Freiburg, Germany-based CellGenix says its T-cell medium â€“ CellGenix TCM â€“ offers a serum-free and xeno-free alternative for rapid expansion of functional human T-cells.
Due to stable glutamine in the formulation, the medium is ready-to-use for T-cell cultures without the need for supplementation with human serum or glutamine. Many current T-cell therapy protocols rely on the addition of human serum.
Eliminating the use of human serum will reduce the failure rate in your manufacturing process due to the high lot-to-lot inconsistencies of serum. Since human serum is a limited resource and might not be available in large quantities it is unsuitable for commercial scale manufacturing. Furthermore, the human origin of serum poses a certain risk of containing adventitious agents and therefore does not meet global regulatory guidelines.
Early onset of T-cell expansion and sustained viability
T-cell culture in CellGenixÂ® TCM results in high cell numbers early after activation and throughout cell culture with high viability. This early onset of T-cell expansion allows for faster T-cell therapy manufacturing, which can significantly reduce your cost of goods.
Promotion of a central memory and early differentiated memory T-cell phenotype
During T-cell culture in CellGenixÂ® TCM a â€śyoungâ€ť phenotype of naĂŻve T-cells/memory stem T-cells (TN/SCM cells) or central memory T-cells (TCM cells) is acquired. These phenotypes represent the most undifferentiated memory T-cell phenotypes, meaning that they have the highest proliferation potential, self-renewal properties and longer survival rates.
It has been shown that the engraftment and persistence of T-cell products in patients is associated with a TCM phenotype, rather than more differentiated memory phenotypes.
TSCM are considered as even less differentiated cells with potentially even better persistence. It has been reported that for CD19 CAR-T cells the expansion of patient-infused cells is correlated with the frequency of CD8+ TSCM-like cells.Â It is therefore beneficial for your T-cell therapy product to obtain a central memory and early differentiated memory T-cell phenotype.
High proportion of cytokine producing cells including polyfunctional cells
An important aspect of T-cell functionality is the secretion of cytokines such as interleukin-2 (IL-2), interferon-gamma (IFN-Îł) and tumor necrosis factor-alpha (TNF-Î±). After cultivation in CellGenixÂ® TCM a high proportion of cytokine producing cells is obtained including polyfunctional cells (expressing more than one cytokine).
A recent report suggests that the combination of cell frequency and cytokine production levels of polyfunctional CD19 CAR-T cells is correlated with the clinical outcome in patients with non-Hodgkin lymphoma. Obtaining cytokine secreting T-cells, in particular polyfunctional cells, could therefore have a positive effect on the therapeutic response of your T-cell therapy product.